Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases
Read More
Archive for Uncategorized
Timmerman Report: Matchpoint gets $100M to take covalent binders into autoimmune disease
Read More
BioSpace: Sanofi-backed Matchpoint launches with $100M for precision covalent medicines
Read More
BioCentury: Matchpoint: a toolkit to create covalent therapies for immunology
Read More
Matchpoint Therapeutics launches with $100 million to deliver on the promise of precision covalent medicines for immune diseases
Read More